These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19236228)

  • 1. Analytical strategies for the screening and evaluation of chemically reactive drug metabolites.
    Wen B; Fitch WL
    Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):39-55. PubMed ID: 19236228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology.
    Baillie TA
    Chem Res Toxicol; 2006 Jul; 19(7):889-93. PubMed ID: 16841955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of drug metabolites.
    Izumi T
    Drug Metab Pharmacokinet; 2011; 26(2):121-2. PubMed ID: 21532211
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery.
    Prakash C; Sharma R; Gleave M; Nedderman A
    Curr Drug Metab; 2008 Nov; 9(9):952-64. PubMed ID: 18991592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimising the potential for metabolic activation in drug discovery.
    Kalgutkar AS; Soglia JR
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):91-142. PubMed ID: 16922655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
    Grillo MP
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of LC-high-resolution MS with 'intelligent' data mining tools for screening reactive drug metabolites.
    Ma S; Chowdhury SK
    Bioanalysis; 2012 Mar; 4(5):501-10. PubMed ID: 22409549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design.
    Brink A; Pähler A; Funk C; Schuler F; Schadt S
    Drug Discov Today; 2017 May; 22(5):751-756. PubMed ID: 27903430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology.
    Erve JC
    Expert Opin Drug Metab Toxicol; 2006 Dec; 2(6):923-46. PubMed ID: 17125409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive metabolites in early drug development: predictive in vitro tools.
    Pelkonen O; Pasanen M; Tolonen A; Koskinen M; Hakkola J; Abass K; Laine J; Hakkinen M; Juvonen R; Auriola S; Storvik M; Huuskonen P; Rousu T; Rahikkala M
    Curr Med Chem; 2015; 22(4):538-50. PubMed ID: 25312212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug bioactivation, covalent binding to target proteins and toxicity relevance.
    Zhou S; Chan E; Duan W; Huang M; Chen YZ
    Drug Metab Rev; 2005; 37(1):41-213. PubMed ID: 15747500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical strategies for identifying drug metabolites.
    Prakash C; Shaffer CL; Nedderman A
    Mass Spectrom Rev; 2007; 26(3):340-69. PubMed ID: 17405144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.
    Thompson RA; Isin EM; Ogese MO; Mettetal JT; Williams DP
    Chem Res Toxicol; 2016 Apr; 29(4):505-33. PubMed ID: 26735163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug metabolite profiling and elucidation of drug-induced hepatotoxicity.
    Tang W
    Expert Opin Drug Metab Toxicol; 2007 Jun; 3(3):407-20. PubMed ID: 17539747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicophores: investigations in drug safety.
    Williams DP
    Toxicology; 2006 Sep; 226(1):1-11. PubMed ID: 16860917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are chemically reactive metabolites responsible for adverse reactions to drugs?
    Williams DP; Kitteringham NR; Naisbitt DJ; Pirmohamed M; Smith DA; Park BK
    Curr Drug Metab; 2002 Aug; 3(4):351-66. PubMed ID: 12093355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of metabonomics at the interface between drug metabolism and safety assessment.
    Waters NJ
    Curr Drug Metab; 2010 Oct; 11(8):686-92. PubMed ID: 20973758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on bioanalytical mass spectrometry and automation in drug discovery.
    Janiszewski JS; Liston TE; Cole MJ
    Curr Drug Metab; 2008 Nov; 9(9):986-94. PubMed ID: 18991596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M; Zhang D; Zhang H; Shyu WC
    Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.